Redeye is encouraged to learn that ISR has signed an agreement with Catalent Inhalation to scale-up ...
Our analyst summarizes the investment case: “Eevia Health offer organic plant extracts for food nutr...
Redeye initiates coverage of Fuud, a Swedish serial acquirer in the functional food sector.
Redeye leaves a comment following Faron Pharmaceutical’s announcement earlier today of a placing of ...
Sedan noteringen har Candles Scandinavia levererat hög omsättningstillväxt och bolaget är väl positi...
On June 22, 2022, Fluicell announced that they have been selected as one out of ten most innovative ...
Redeye updates its view on Energy Save post its Q4’2021/22 report.
Redeye makes an adjustment to the project’s LOA based on results from BT-001’s phase I trial, part A...
Redeye is encouraged by the news from Evaxion concerning good pre-clinical results of EVX-03 and the...
Redeye comments on the news regarding ISAB's latest IRS order worth SEK 518,000.
Q2 report due on 15 July Dedicare is taking market share in a growing market New value range of SEK ...
We trim our growth assumptions Slower rental growth hedges against price fall 11x ’23e P/IFPM and 5...
Redeye comments on Energy Save’s Q4’21/22 report. The report showed strong growth and profitability ...
Bolaget genomförde en riktad emission i syfte att stärka ägarsidan vilket påverkade resultatet för Q...
Redeye provides a comment on the result of the rights issue.
Redeye is encouraged to learn that Devyser has been awarded a tender from Héma-Québec in Québec, Can...
FDA decision expected in Q3, potential sales start in Q4 DiviTum shown complimentary to ctDNA Q4’21/...
Redeye comments on Evolution’s acquisition of Nolimit City which is a small acquisition that expands...
CombiGene fortsätter att utvecklingen av CG01 i samarbete med Spark Therapeutics.
Redeye endorses the news that SenzaGen has received its largest order so far with a value of SEK 4.
